Fig. 7

Gene set analyses of nasal epithelial cell mRNA expression from digitoxin-treated CF patients. (a) Pro-inflammatory gene signature. 81 of 84 genes in the in vitro digitoxin/gene therapy-dependent gene signature for inflammation found in the in vivo affymetrix array. (b) Pro-fibrosis gene signature. 46 of 49 genes in the in vitro digitoxin/gene therapy-dependent gene signature for fibrosis found in the in vivo affymetrix array. (c) Epithelial differentiation signature. 81 of 82 genes in the in vitro digitoxin/gene therapy-dependent gene signature for epithelial differentiation found in the in vivo affymetrix array. Data and color-coding: Post- vs. pre-treatment Affymetrix microarray mRNA expression log2 fold- changes of nasal epithelial cell biopsies from CF patients treated with 0.1 mg digitoxin/day for 28 days. Average log2 fold-changes for all array genes (black lines) and sub-sets of genes defining three overlapping digitoxin/gene therapy gene sets identified from in vitro RNA-seq data (colored lines; green for down-regulated sets and red for up-regulated sets) are shown. Numbers of genes present on array in defined gene sets are displayed, along with two-tailed Mann-Whitney-Wilcoxon U-test p-values for set genes versus all genes. * indicates p < 0.05